Hypoglycemia in a Patient With Metastatic Gastrointestinal Stromal Tumor: Is Chemotherapy a Reasonable Option for Symptom Control?

Tumor induced hypoglycemia is a rare paraneoplastic phenomenon. However, hypoglycemia may also occur in solid tumors of epithelial or mesenchymal origin. Hypoglycemia caused by these types of tumours is referred to as non-islet cell tumour hypoglycemia (NICTH). Sunitinib is a drug that novel, oral, multitargeted tyrosine kinase. The biologic bases of the activity of sunitinib in patients with GISTs that are target multiple signaling pathways in tumor, stromal, and endothelial compartments. In this report, we describe a case of metastatic gastrointestinal stromal tumor (GIST) presented with loss of consciousness due to hypoglycemia caused or worsened by sunitinib. In our opinion, who the patients with imatinib mesylate and sunitinib malate intolerant GIST, combination chemotherapy consisting of cisplatin and etoposid can be useful in the palliative setting, like our case

Hypoglycemia in a Patient With Metastatic Gastrointestinal Stromal Tumor: Is Chemotherapy a Reasonable Option for Symptom Control?

Tumor induced hypoglycemia is a rare paraneoplastic phenomenon. However, hypoglycemia may also occur in solid tumors of epithelial or mesenchymal origin. Hypoglycemia caused by these types of tumours is referred to as non-islet cell tumour hypoglycemia (NICTH). Sunitinib is a drug that novel, oral, multitargeted tyrosine kinase. The biologic bases of the activity of sunitinib in patients with GISTs that are target multiple signaling pathways in tumor, stromal, and endothelial compartments. In this report, we describe a case of metastatic gastrointestinal stromal tumor (GIST) presented with loss of consciousness due to hypoglycemia caused or worsened by sunitinib. In our opinion, who the patients with imatinib mesylate and sunitinib malate intolerant GIST, combination chemotherapy consisting of cisplatin and etoposid can be useful in the palliative setting, like our case

Outcome of 561 non-metastatic triple negative breast cancer patients: Multi-center experience from Turkey

Purpose: Triple-negative breast cancers account for 15% of breast carcinomas and, when present as early-stage disease, they are associated with higher rates of recurrence and early distant metastasis risk when compared to hormone receptor positive and human epidermal growth factor receptor (HER-2) positive breast cancers. In this study we aimed to explore the basic clinicopathological characteristics, prognostic factors and recurrence patterns of non-metastatic triple negative breast cancer patients